On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference. A recording of the session is available below.
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is …
… Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in … machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase Acting on RNA), a protein which is …